Biogen’s Henshaw Insists Data Is Key In Bolstering Biosimilars
Data published by Biogen is a key factor in driving uptake and acceptance of its biosimilars, the firm’s head of biosimilars, Ian Henshaw, told Generics Bulletin in an exclusive interview.
You may also be interested in...
In the third and final part of an exclusive interview with Generics Bulletin, Samsung Bioepis CEO Christopher Hansung Ko talks about the importance of real-world data in bolstering biosimilars, as well as outlining the firm’s future pipeline.
Samsung Bioepis has entered a fifth continent by launching its Brenzys etanercept biosimilar in Brazil, as part of global expansion plans for the business.
Samsung Bioepis’ Imraldi adalimumab biosimilar has been granted a European label update that approves the product to be stored in non-refrigerated conditions for up to 28 days.